Ciclosporin and tacrolimus are both calcineurin inhibitors - the former binding to calcineurin as a complex with cyclophillin A, and the latter as a complex with FKBP1.
Sirolimus also binds to FKBP12, but this complex inhibits cell proliferation by binding to the mammalian target of rapamycin (mTOR).
Mycophenolate mofetil, not azathioprine, acts through inosine monophosphate dehydrogenase inhibition.
Showing posts with label immunosuppresive therapy. Show all posts
Showing posts with label immunosuppresive therapy. Show all posts
Clinically useful monoclonal antibodies in treatment
Basiliximab and dacluzimab are antibodies to the IL2 receptor (CD25) expressed on activated T cells. They are used as induction therapy in renal transplantation.
Antibodies to CD3 (OKT3) are used in the treatment of renal transplant rejection.
Rituximab is an antibody to CD20 expressed on B cells and is used in B cell lymphomas.
Antibodies to CD154 (CD40 ligand - a molecule pivotal in T cell costimulation) had great promise in transplantation and autoimmunity. However, trials in humans have stopped after early work showed a high incidence of thrombosis, probably because CD154 is expressed on activated human platelets.
Antibodies to CD8 have not been used clinically.
Antibodies to CD3 (OKT3) are used in the treatment of renal transplant rejection.
Rituximab is an antibody to CD20 expressed on B cells and is used in B cell lymphomas.
Antibodies to CD154 (CD40 ligand - a molecule pivotal in T cell costimulation) had great promise in transplantation and autoimmunity. However, trials in humans have stopped after early work showed a high incidence of thrombosis, probably because CD154 is expressed on activated human platelets.
Antibodies to CD8 have not been used clinically.
Subscribe to:
Posts (Atom)